This discussion covers the important issues related to Diabetic Macular Edema, as reported from the 2012 annual meeting of the American Society of Retina Specialists in Las Vegas, Nevada, in the format of case-study scenarios for the clinical practice.

Dr. Adrienne W. Scott, Assistant Professor of Ophthalmology at the Wilmer Eye Institute at Johns Hopkins in Baltimore will present patient case scenarios which: apply the result of recent trials evaluating diabetic macular edema and proliferative diabetic retinopathy (PDR) to clinical scenarios, describe the rationale for the use of anti-VEGF in the treatment of diabetic macular edema and PDR, and determine patient characteristics that favor one treatment modality over another

Dr. Susan Bressler, MD, The Julia G. Levy, PhD,Professor of Ophthalmology at the Wilmer Eye Institute at the Johns Hopkins University School of Medicine in Baltimore, MD. Dr. Bressler will present patient case scenarios which will: develop an appropriate diagnostic assessment of patient presenting with symptoms of neovascular macular degeneration, apply the results of the pivotal phase 3 studies of ranibizumab to eyes with chorodial neovascular lesions that are either predominately classic, minimally classic, or occult with no classic components in the lesion composition, and integrate the results of the CATT study inot their clinical practice

Dr. Peter Campochiaro, the Eccles Professor of Ophthalmology and Neurosciences at the Wilmer Eye Institute at The Johns Hopkins University in Baltimore will present patient case scenarios which will: describe the potential benefits and risks of intraocular ant-VEGF drugs in treating retinal vein occlusions; determine patient characteristics that favor one treatment modality over another; explain the potential benefits and risks of intraocular steroids in treating retinal vein occlusions

Dr. Jennifer Lim, Professor of Ophthalmology and Director of Retina Service at the University of Illinois in Chicago, will present case scenarios which will address treatment options for DME, investigate anti-VEGF therapy, enumerate mangement options for patients with coexisting DME and PDR, and discuss management options for patients with coexisting DME and cataract.